Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 351–360 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 351
- Medicine slug
- cysteamine
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 4
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
1.4 hours
- Numeric value
- 1.4
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f495b76d-96c6-48e5-8fa3-30a4336628eb (opens source in a new tab)
Cysteamine label
Version not recorded · Effective date not recorded
Following repeated oral administration of 225 to 550 mg cysteamine bitartrate, the mean time to maximum plasma concentration (T max ) occurred at about 1.4 hours post dose with mean steady-state peak plasma concentration (C max ) and area under the concentration-time curve (AUC) of 2.6 µg/mL and 6.3 µg∙hr/mL, respectively.
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3a3ec28-f746-463a-bb92-3bc8826db09e (opens source in a new tab)
Cysteamine label
Version not recorded · Effective date not recorded
After the administration of a single dose of PROCYSBI, peak concentrations of cysteamine were observed at 3 hours post-dose.
Projected row 352
- Medicine slug
- cysteamine
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 4
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
156 L
- Numeric value
- 156
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f495b76d-96c6-48e5-8fa3-30a4336628eb (opens source in a new tab)
Cysteamine label
Version not recorded · Effective date not recorded
The apparent volume of distribution and apparent plasma clearance of cysteamine were 156 L and 1.2 L/min, respectively.
382 L
- Numeric value
- 382
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3a3ec28-f746-463a-bb92-3bc8826db09e (opens source in a new tab)
Cysteamine label
Version not recorded · Effective date not recorded
The volume of distribution (Vd/F) was 382 L for PROCYSBI compared with 198 L for immediate-release cysteamine bitartrate.
Projected row 353
- Medicine slug
- cytarabine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
1 to 3 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90f5c7ab-9f15-487d-ba69-ee4107434bcc (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be2668b-d76f-4c65-aea9-86c5c40889a2 (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:446f6765-5375-6368-4755-4944574f5721 (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b366382-c8d1-4344-86b7-f65e92a8952b (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:681b5dc4-4fcf-4fab-ad78-02cb9a4a5dd0 (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4fdc56e-efd7-4825-a518-ef430b2b3df0 (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bc7f6c2-4b16-449b-b383-76106540206c (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3a8c0e9-19ed-49b7-8464-11e8806f47fd (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ab50348-ca78-46a5-aba6-c35b6b21fbfe (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb0db038-4a65-42c7-aa79-5c88309061df (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21e8e8e6-3f85-4fdd-8452-c9d14d2ef69a (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:277597b0-7d85-40a3-a34a-70c6a883fc6d (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc2fa221-ea56-48b8-8304-42cd81b8463b (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8105e590-fc7e-45b7-9604-c2d0d1be5eac (opens source in a new tab)
Cytarabine label
Version not recorded · Effective date not recorded
There is an initial distributive phase with a half-life of about 10 minutes, followed by a second elimination phase with a half-life of about 1 to 3 hours.
Projected row 354
- Medicine slug
- dabigatran-etexilate
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
75%
- Numeric value
- 75
- Unit
- %
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13649035-a498-4e31-a7ea-8b18cedceca7 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd47a015-ff90-d7a7-8dcb-4e6e31a68071 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the powder is taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:369b945d-5bda-4773-910a-d0adef7f0f39 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ac558a-b375-f3c1-e063-6394a90aa901 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27e95caf-7938-ef8e-e063-6394a90a6a1a (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a608e019-db9a-d6fb-cd0d-cecc1351a2b1 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b196b1f-408e-4615-b980-9f822adff835 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the mini-tablets and pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c24e235-218b-438e-9456-42c18ff01913 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b3bfc1-4fcb-4eb9-a611-02c27c05c56e (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4e3b992-621a-43a5-be59-eeb5083fd2b4 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baafb5be-ffe6-4755-a7ab-817b3c9b222d (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:834a3c5f-b723-4bcb-a560-dc305dd0d829 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f79088b-b353-485a-9df4-6f5088f5bd0f (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31d27e9-5502-43c5-83fa-89608c014b7a (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8ec82a-c367-40dc-9302-e1896fcb05ea (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b76b79ce-b7dd-4390-b40e-71ae6c477d10 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation based on a single-dose relative bioavailability study.
Projected row 355
- Medicine slug
- dabigatran-etexilate
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 0.952381
- Recorded readings
12 to 17 hours
- Numeric value
- 12
- Unit
- hours
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13649035-a498-4e31-a7ea-8b18cedceca7 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd47a015-ff90-d7a7-8dcb-4e6e31a68071 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:369b945d-5bda-4773-910a-d0adef7f0f39 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ac558a-b375-f3c1-e063-6394a90aa901 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27e95caf-7938-ef8e-e063-6394a90a6a1a (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a608e019-db9a-d6fb-cd0d-cecc1351a2b1 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b196b1f-408e-4615-b980-9f822adff835 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c24e235-218b-438e-9456-42c18ff01913 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b3bfc1-4fcb-4eb9-a611-02c27c05c56e (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4e3b992-621a-43a5-be59-eeb5083fd2b4 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baafb5be-ffe6-4755-a7ab-817b3c9b222d (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:834a3c5f-b723-4bcb-a560-dc305dd0d829 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f79088b-b353-485a-9df4-6f5088f5bd0f (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31d27e9-5502-43c5-83fa-89608c014b7a (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8ec82a-c367-40dc-9302-e1896fcb05ea (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b76b79ce-b7dd-4390-b40e-71ae6c477d10 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The half-life of dabigatran in healthy adult subjects is 12 to 17 hours.
9 to 11 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ac0a64a-8666-45f7-9d4f-40fd894f7e6d (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The elimination half-life of dabigatran in pediatric patients receiving pellets is approximately 9 to 11 hours.
Projected row 356
- Medicine slug
- dabigatran-etexilate
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
50 to 70 L
- Numeric value
- 50
- Unit
- L
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5937f27-88c7-4c4a-801e-4c8945008982 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13649035-a498-4e31-a7ea-8b18cedceca7 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd47a015-ff90-d7a7-8dcb-4e6e31a68071 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:369b945d-5bda-4773-910a-d0adef7f0f39 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ac558a-b375-f3c1-e063-6394a90aa901 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27e95caf-7938-ef8e-e063-6394a90a6a1a (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a608e019-db9a-d6fb-cd0d-cecc1351a2b1 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b196b1f-408e-4615-b980-9f822adff835 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c24e235-218b-438e-9456-42c18ff01913 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ac0a64a-8666-45f7-9d4f-40fd894f7e6d (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b3bfc1-4fcb-4eb9-a611-02c27c05c56e (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4e3b992-621a-43a5-be59-eeb5083fd2b4 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baafb5be-ffe6-4755-a7ab-817b3c9b222d (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:834a3c5f-b723-4bcb-a560-dc305dd0d829 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f79088b-b353-485a-9df4-6f5088f5bd0f (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31d27e9-5502-43c5-83fa-89608c014b7a (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8ec82a-c367-40dc-9302-e1896fcb05ea (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b76b79ce-b7dd-4390-b40e-71ae6c477d10 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2 (opens source in a new tab)
Dabigatran Etexilate label
Version not recorded · Effective date not recorded
The volume of distribution of dabigatran is 50 to 70 L.
Projected row 357
- Medicine slug
- dacarbazine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6b97e41-5f15-498c-abfb-d8443ea4d216 (opens source in a new tab)
Dacarbazine label
Version not recorded · Effective date not recorded
Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged dacarbazine in the urine is 40% of the injected dose in 6 hours. 1 Dacarbazine is subject to renal tubular secretion rat
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d81315c-7021-4091-b703-ad135390c936 (opens source in a new tab)
Dacarbazine label
Version not recorded · Effective date not recorded
Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64037f45-6245-49f0-9ae8-18d75753ae1f (opens source in a new tab)
Dacarbazine label
Version not recorded · Effective date not recorded
Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged dacarbazine in the urine is 40% of the injected dose in 6 hours. 1 Dacarbazine is subject to renal tubular secretion rat
Projected row 358
- Medicine slug
- dalbavancin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
8.5 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2ec45e-48a2-4887-8ab0-9244eb39a394 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
Dalbavancin Pharmacokinetic Parameters in Healthy Subjects All values are presented as mean (% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f4a5924-96d7-445a-b75f-2c0e1ffd2dea (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
(% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a20d077-a5ba-4af3-a2d6-499c25b816d8 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
Dalbavancin Pharmacokinetic Parameters in Healthy Subjects All values are presented as mean (% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:966995bb-9d92-434d-b75a-1786072b81c9 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
(% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
(% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b4674d8-4d1e-4728-8465-d42ada33fa5c (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
(% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c188995-ab05-45c3-a3af-5b1bcd655fdc (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
(% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects.
Projected row 359
- Medicine slug
- dalbavancin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
93%
- Numeric value
- 93
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2ec45e-48a2-4887-8ab0-9244eb39a394 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f4a5924-96d7-445a-b75f-2c0e1ffd2dea (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a20d077-a5ba-4af3-a2d6-499c25b816d8 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:966995bb-9d92-434d-b75a-1786072b81c9 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1 (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b4674d8-4d1e-4728-8465-d42ada33fa5c (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c188995-ab05-45c3-a3af-5b1bcd655fdc (opens source in a new tab)
Dalbavancin label
Version not recorded · Effective date not recorded
The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment.
Projected row 360
- Medicine slug
- dalfampridine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
96%
- Numeric value
- 96
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:354a97e8-35c8-418b-91b2-9e8e066cec65 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of extended-release dalfampridine tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:302c8270-4711-4ca4-bee8-be0738fbe094 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of extended release dalfampridine tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed826777-b8c4-4d35-aa64-a4c28452baa8 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of extended-release dalfampridine tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e10b2d92-2824-4395-8883-6fd52c784aa4 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of dalfampridine extended-release tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:688eb479-debc-4cfc-a74d-14828c347049 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of extended release dalfampridine tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:974fb2af-7012-4989-b330-e44a31c9c3e5 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of extended release AMPYRA tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1134ac0f-59c1-a20b-e063-6294a90affcc (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of dalfampridine extended-release tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40dcc84-b839-44aa-94f2-886fb1c3d75c (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of dalfampridine extended-release tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of extended release AMPYRA tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43996322-7d83-4420-9e61-4ed37f710fee (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of extended release dalfampridine tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d61e15fa-0334-49a0-ab41-c9a36b726b57 (opens source in a new tab)
Dalfampridine label
Version not recorded · Effective date not recorded
Absolute bioavailability of dalfampridine extended-release tablets have not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=350Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.